NBI-31772 (5-100 μg; siv; administered at the onset of ischemia) dose-dependently reduces total infarct volume and cortical infarct volume at the onset of ischemia in rats with middle cerebral artery occlusion (MCAO) model[2].
NBI-31772 (50 μg; i.v.; administered 0, 1, 2, or 3 hours after MCAO) reduces cortical infarct size and brain swelling in rats with intraluminal suture MCAO model[2].
NBI-31772 (0.4 μM/strip; i.p.; 4 h) induces germinal vesicle rupture in zebrafish[4].
| Animal Model: | MCAO model rats[2] |
| Dosage: | 5, 50 and 100 μg |
| Administration: | siv; Drug administration during ischemic episodes |
| Result: | Had similar effects on total lesion volume at the 50 and 100 μg doses.
Affected striatal lesion volume at the 50 μg dose. |
| Animal Model: | Intraluminal suture MCAO model rats[2] |
| Dosage: | 50 μg |
| Administration: | i.v.; Administration 0, 1, 2, or 3 hours after MCAO |
| Result: | The greatest lesion reduction was observed when the drug was administered immediately after MCAO. |
